About this trial
The goal of this study is to evaluate if indocyanine green (ICG) fluorescence imaging helps reduce complications in bowel surgery performed during gynecologic cancer operations.
The main question it aims to answer is: Does using ICG fluorescence imaging during bowel anastomosis reduce the rate of complications such as leaks, infections, and abscesses within 30 days after surgery? Participants are women aged 18 and older undergoing surgery for gynecologic cancers (such as ovarian, uterine, cervical, or vulvar cancer). During surgery, investigators will inject ICG intravenously, then use a special near-infrared camera to see how well blood flows at the anastomosis site. The investigators will then decide if the reconnection is good enough or needs adjustment.
Researchers will record any complications within the first 30 days after surgery to understand if this imaging method helps reduce surgical risks.
Eligibility criteria
Qualifiers
Female patients aged 18 years or older.
Diagnosis of gynecologic cancer (ovarian, endometrial, cervical, vulvar) requiring surgical treatment.
Planned bowel resection and anastomosis during gynecologic oncology surgery.
Ability and willingness to provide informed consent.
Disqualifiers
Known allergy or hypersensitivity to indocyanine green (ICG).
Pregnancy or breastfeeding at the time of surgery.
Severe liver or kidney dysfunction limiting the use of ICG.
Trial design
Treatments tested in this trial
- Indocyanine Green
- Near-Infrared Fluorescence Imaging System